Prospective, Randomized Study of Single Compared With Double Autologous Stem-Cell Transplantation for Multiple Myeloma: Bologna 96 Clinical StudyMichèle Cavo, Michele Baccarani, Patrizia Tosi et al.|Journal of Clinical Oncology|2007Cited by 374
Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapyMichèle Cavo, Michele Baccarani, Elena Zamagni et al.|Blood|2002Cited by 152
Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma.Patrizia Tosi, Michèle Cavo, Elena Zamagni et al.|PubMed|2002Cited by 111
Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label studyPaola Tacchetti, Gianpietro Semenzato, R. Foà et al.|The Lancet Haematology|2020Cited by 58
A Phase III Study of Double Autotransplantation Incorporating Bortezomib-Thalidomide-Dexamethasone (VTD) or Thalidomide-Dexamethasone (TD) for Multiple Myeloma: Superior Clinical Outcomes with VTD Compared to TD.Michèle Cavo, Michele Baccarani, Paola Tacchetti et al.|Blood|2009Cited by 48